Primary Immune Deficiency

New immune globulin IV treatment submitted for approval in key markets

Published in Cancer Weekly, October 15th, 2002

Bayer Biological Products (BP) (BAY) announced that it has submitted its next generation immune globulin intravenous (IGIV) product for regulatory approval in the United States, Canada, and Germany.

Submitted under the trade name Gamunex, Bayer BP's new IGIV-C product introduces a breakthrough purification process, Caprylate/Chromatography, designed to establish new standards in product purity and supply reliability. Gamunex is the first newly developed IgIV product to be submitted to the U.S. Food and Drug Administration (FDA) in over a decade and its production process differs significantly from traditional IGIV manufacturing processes that are based on methods first...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-10-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry